Component
High-contrast visual acuity in ZVF trial
High-contrast visual acuity in ZVF trial. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The zeaxanthin arm showed a 1.5-line improvement in high-contrast acuity; the indexed result does not establish between-group superiority.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/zeaxanthin-research/22027699.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e", "start_char": 0, "end_char": 3131, "text_sha256": "849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e"}
- experimental_model
- Small randomized active-comparator ZVF trial
- exposure
- One year; 8 mg zeaxanthin, 8 mg zeaxanthin plus 9 mg lutein, or 9 mg lutein comparator
- limitations
- The so-called faux placebo was active lutein. Small unequal arms, multiple outcomes and borderline tests limit claims of superiority; proposed competition was not directly tested.
- nutrient_topic
- Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect. · Dietary (3R,3-prime-R)-zeaxanthin
- organism
- 60 patients with mild-to-moderate AMD; 57 men
- plain_language
- A within-arm improvement is weaker evidence than a clear treatment comparison.
- primary_references
- [zeaxanthin-p22027699] Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. (2011). https://pubmed.ncbi.nlm.nih.gov/22027699/ DOI: 10.1016/j.optm.2011.08.008
- tissue_or_cell_type
- Macular pigment and visual tasks
Zeaxanthin: metabolism, signaling and nutrient connections (2026-09-17) · lines 990–1001
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Small randomized active-comparator ZVF trial · source_derived_draft · unverified_draft
### zeaxanthin-zvf-acuity The zeaxanthin arm showed a 1.5-line improvement in high-contrast acuity; the indexed result does not establish between-group superiority. Condition category: normal nutrient_topic: Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect. plain_language: A within-arm improvement is weaker evidence than a clear treatment comparison. organism: 60 patients with mild-to-moderate AMD; 57 men tissue_or_cell_type: Macular pigment and visual tasks experimental_model: Small randomized active-comparator ZVF trial limitations: The so-called faux placebo was active lutein. Small unequal arms, multiple outcomes and borderline tests limit claims of superiority; proposed competition was not directly tested. exposure: One year; 8 mg zeaxanthin, 8 mg zeaxanthin plus 9 mg lutein, or 9 mg lutein comparator evidence_span: {"source_cache": "artifacts/zeaxanthin-research/22027699.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e", "start_char": 0, "end_char": 3131, "text_sha256": "849b03f2bf0734e12b654e662e0a15e5f347415de7b0bbabe2cdc0d7bad85e3e"} [zeaxanthin-p22027699] Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. (2011). https://pubmed.ncbi.nlm.nih.gov/22027699/ DOI: 10.1016/j.optm.2011.08.008
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.